CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
DLI of the 20 fraction of the UCBTdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02328885
NCT02328885Phase 2Completed
CompareCT.gov

Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation

Banc de Sang i Teixits·interventional·Posted Dec 31, 2014·Updated Dec 8, 2021

In Brief

A Phase 2 clinical trial evaluating DLI of the 20 fraction of the UCBT for Leukemia. Completed, enrolled 17 participants across 5 sites.

Detailed Summary

Pilot, multicentric, open-label, single-arm, phase I-II clinical trial to evaluate the safety and efficacy of a novel Umbilical Cord Blood Transplantation (UCBT) platform, that consists of a UCBT of the 80 fraction, followed by a Donor Lymphocyte Infusion (DLI) of the 20 fraction (between 60 and 90 days after transplantation).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesSpain
CollaboratorsHospital Vall d'Hebron, Hospital de Sant Pau, Hospital Universitari de Bellvitge, Germans Trias i Pujol Hospital, Fundacion IMIM

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 31, 2014
Enrollment StartJul 1, 2014
Primary CompletionMar 22, 2017
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.5 years ago

Interventions

DLI of the 20 fraction of the UCBTdrug

Administration of 20 fraction of the UCBT